Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 697–720 of 9,907 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Single Arm Clear all
Recruiting Phase 1Phase 2 Interventional

A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

NCT04370587
View directory record Official record
Conditions
Solid Tumor, Melanoma, HNSCC, Sarcoma, Squamous Cell Carcinoma, NSCLC
Interventions
T3011, T3011 + pembrolizumab
Biological · Combination Product
Lead sponsor
ImmVira Pharma Co. Ltd
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
6
States / cities
Gilbert, Arizona • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 25, 2026, 9:40 AM EDT
Terminated Not applicable Interventional

Integrating WIC With Early Childhood Systems of Developmental Care

NCT04159038
View directory record Official record
Conditions
Developmental Disability, Food Assistance, Health Care Disparity
Interventions
Intervention Group, Control group
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
Up to 54 Months
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Bend, Oregon • Grants Pass, Oregon • Hillsboro, Oregon + 1 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 25, 2026, 9:40 AM EDT
Not yet recruiting No phase listed Observational

Pharmacokinetics of CFTR Modulators in Pregnant Individuals and in Postpartum Breastfeeding Mothers

NCT04940533
View directory record Official record
Conditions
Cystic Fibrosis, Pregnancy
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Jet Injection for Influenza

NCT01688921
View directory record Official record
Conditions
Influenza, Human
Interventions
AFLURIA vaccine (2012-2013 formulation), Needle-Syringe, Stratis needle-free injection device
Biological · Device
Lead sponsor
PharmaJet, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
1,250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
3
States / cities
Fort Collins, Colorado • Loveland, Colorado
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

Treatment With Acalabrutinib Post Blood or Marrow Transplantation in Subjects With Mantle Cell Lymphoma

NCT04402138
View directory record Official record
Conditions
Mantle Cell Lymphoma
Interventions
Acalabrutinib
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
4
States / cities
Denver, Colorado • New Orleans, Louisiana • Kansas City, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated May 13, 2025 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Reactions to Warnings on Hookah Ads

NCT03723616
View directory record Official record
Conditions
Reactions to Warnings, Hookah Smoking
Interventions
Ads Only, Ads with text-only health warning labels (HWLs), Ads with text + graphic health warning labels (HWLs)
Behavioral
Lead sponsor
Duke University
Other
Eligibility
18 Years to 34 Years
Enrollment
2,588 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 25, 2026, 9:40 AM EDT
Enrolling by invitation Not applicable Interventional

Patient-centered Precision Medicine Lab Result Communication for Older Adults

NCT07391904
View directory record Official record
Conditions
Chronic Kidney Disease (CKD), Health Communication, Patient Comprehension
Interventions
Chronic Kidney Disease (CKD) Lab Result Communication Tool
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
65 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 24, 2026 · Synced Oct 25, 2026, 9:40 AM EDT
Terminated Not applicable Interventional Results available

At-Home Dermoscopy Artificial Intelligence

NCT05321784
View directory record Official record
Conditions
Malignant Skin Neoplasm
Interventions
Dermoscopy, Digital Photography, Self-Skin Examination, Skin Examination with Sklip, Skin Examination, Survey Administration
Other · Procedure · Device
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
21 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Dec 29, 2025 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

The Houston HIITBAC for African Americans

NCT02253433
View directory record Official record
Conditions
Asthma
Interventions
Enhanced Clinic Care, Enhanced Clinic Care + Home Intervention
Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Phase 4 Interventional

A Phase 4 Study Investigating the Efficacy of Retaine™ in Managing Signs and Symptoms Associated With Dry Eye Syndrome

NCT02139033
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
Retaine™
Drug
Lead sponsor
Ocusoft, Inc.
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 11, 2014 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Early Phase 1 Interventional

Safety and Preliminary Efficacy of Adipose Derived Stem Cells and Low Frequency Ultrasound in PAD

NCT02756884
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
LoFU and aADSC, adipose derived stem cells
Biological
Lead sponsor
Arkansas Heart Hospital
Other
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 26, 2019 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Phase 2 Interventional Results available

A Study of Onapristone ER Alone Or In Combination With Anastrozole in Gynecologic Cancers That Respond to Progesterone

NCT03909152
View directory record Official record
Conditions
Granulosa Cell Ovarian Cancer, Low Grade Serous Ovarian/ Primary Peritoneal Cancer, Endometrioid Endometrial Cancer
Interventions
Onapristone ER, Onapristone ER + Anastrozole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Oct 25, 2026, 9:40 AM EDT
Recruiting Phase 2 Interventional

Single-Fraction SBRT Versus Standard Palliative Radiation Therapy in Treating Patients With Metastatic Cancer

NCT04068649
View directory record Official record
Conditions
Metastatic Malignant Neoplasm
Interventions
Palliative Radiation Therapy, Quality-of-Life Assessment, Questionnaire Administration, Stereotactic Body Radiation Therapy
Radiation · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
1,500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
3
States / cities
Buffalo, New York • East Hills, New York • West Islip, New York
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 25, 2026, 9:40 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

NCT02621021
View directory record Official record
Conditions
Melanoma
Interventions
young TIL, Pembrolizumab, Aldesleukin, Fludarabine, Cyclophosphamide
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 72 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

Optimizing Physical Activity Outcomes After Total Knee Arthroplasty

NCT03226106
View directory record Official record
Conditions
Total Knee Arthroplasty, Osteoarthritis
Interventions
Physical Activity Behavior Intervention, Attention Control
Behavioral · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
50 Years to 85 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Phase 2 Interventional

Alvocidib in Patients With Previously Treated Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia Arising From Chronic Lymphocytic Leukemia (CLL)

NCT00464633
View directory record Official record
Conditions
Leukemia, Lymphocytic, Chronic
Interventions
alvocidib
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
13
States / cities
San Diego, California • San Francisco, California • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2013 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

Efficacy of Functional Electrical Stimulation (FES) in Persons Receiving Botulinum Neurotoxin for Upper Extremity Spasticity

NCT00462449
View directory record Official record
Conditions
Upper Extremity Spasticity, Stroke, Acquired Brain Injury
Interventions
Functional Electrical Stimulation (FES) through the Ness H200
Device
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2014 · Synced Oct 25, 2026, 9:40 AM EDT
Recruiting Phase 2 Interventional

18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism

NCT04205604
View directory record Official record
Conditions
Congenital Hyperinsulinism
Interventions
18F-Fluoro Dopa Imaging
Drug
Lead sponsor
Miguel Pampaloni
Other
Eligibility
0 Days to 18 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Comparing the Pharmacokinetics (PK) of ABP 501 40 mg/0.4 mL (ABP 501-HCF) and ABP 501 40 mg/0.8 ml (ABP 501-LCF) in Healthy Adult Participants

NCT05909852
View directory record Official record
Conditions
Adalimumab
Interventions
ABP 501-HCF, ABP 501-LCF
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
372 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
3
States / cities
Cypress, California • South Miami, Florida • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 25, 2026, 9:40 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Pilot Influenza Challenge Study

NCT07063849
View directory record Official record
Conditions
Influenza
Interventions
A/Texas
Biological
Lead sponsor
Daniel Hoft, MD, PhD
Other
Eligibility
18 Years to 45 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 25, 2026, 9:40 AM EDT
Withdrawn Phase 2 Interventional

Efficacy of Tranexamic Acid (TXA) in Humerus ORIF

NCT05802238
View directory record Official record
Conditions
Fracture Humerus
Interventions
Tranexamic acid (TXA), Saline
Drug · Other
Lead sponsor
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Other
Eligibility
18 Years to 100 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 13, 2024 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Breathing Room Intervention to Achieve Better Lung Health in Older Adults

NCT05330780
View directory record Official record
Conditions
Breathing, Aging
Interventions
Breathing Room
Other
Lead sponsor
University of Wisconsin, Milwaukee
Other
Eligibility
45 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 1, 2023 · Synced Oct 25, 2026, 9:40 AM EDT
Completed Not applicable Interventional Results available

Comparative Effectiveness Research to Enhance Outcomes in African-Americans With Obstructive Sleep Apnea

NCT01997723
View directory record Official record
Conditions
Obstructive Sleep Apnea
Interventions
Portable monitoring, Polysomnography, Home portable monitoring, Laboratory portable monitoring
Device · Other
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 29, 2024 · Synced Oct 25, 2026, 9:40 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma

NCT03817320
View directory record Official record
Conditions
ALL, Childhood, Lymphoblastic Lymphoma, Childhood, Lymphoblastic Leukemia, Acute, Childhood
Interventions
Ixazomib, Vincristine, Dexamethasone, Asparaginase, Doxorubicin, Methotrexate (IT), Triple IT (Methotrexate, Hydrocortisone, Cytarabine), Leucovorin
Drug
Lead sponsor
Therapeutic Advances in Childhood Leukemia Consortium
Other
Eligibility
1 Year to 21 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
17
States / cities
Los Angeles, California • Orange, California • Washington D.C., District of Columbia + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Oct 25, 2026, 9:40 AM EDT